Thymosin-A1 and cancer

Over a decade ago a report in Future Medicine claimed that “Thymosin-based therapies have the potential to treat the two most prevalent causes of death in the USA – cancer and cardiovascular disease.”

A more recent report “strongly recommended” thymosin-A1 among cancer patients undergoing chemotherapy.  Thymosin-A1 is also posed as a “vaccine enhancer.”  Thymosin-A1 can also be added to vaccines as an adjuvant.

Thymosin-A1 and cancer

Thymosin-A1 is an already-approved drug for immunodeficiency diseases and has direct therapeutic and even curative application as an anti-cancer treatment via its ability to minimize immune-suppression and inhibit cancer growth factors (vascular endothelial growth factor or VEGF) and therefore can also serve to avert vision loss from growth of abnormal blood vessels in the visual center of the eyes (macular degeneration).

Thymosin-A1 has been successfully used to treat lung cancer patients.  The most recent research advocates for thymosin A-1 for breast cancer.

At the very least, thymosin A-1 could be used to treat opportunistic infections among patients undergoing cancer chemotherapy.

Foot-dragging in modern medicine

Thymosin A-1 was first isolated in the late 1970s.  Given that the thymus gland is the main immune organ, there is no adequate explanation for the foot-dragging in modern medicine to implement T-cell elevating thymosin treatment among immune-compromised patients, advocated in 1976 and even earlier.  More than four decades have elapsed since thymosin-A1 was first isolated and early studies “did not fall short of expectations.”

Thymosin-A1 is licensed in 37 countries for the treatment of hepatitis and as an immune adjuvant and stimulant. Thousands of patients have been safely and successfully treated with thymosin-A1 (T-A1 “safety profile is excellent and is virtually devoid of toxicity,” which is more than can be said about vaccines).

This “amazing” remedy has been overshadowed by lesser effective monoclonal antibody drugs (remdesivir) that are approved for treatment of COVID-19.

Oral thymosin-A1

Oral thymosin-A1 is orally absorbed and is the most potent ingredient in thymus powder, exhibiting 10-10,000 times more biological activity than raw thymus extract.  Pure chemically synthetic thymosin-A1 is not affordable for most people.  (Thymus gland extracts are not to be taken by healthy adults.)

Indirect thymosin booster: zinc

The trace mineral zinc is considered the gatekeeper of immune surveillance, the mechanism by which white blood cells seek out and destroy abnormal organisms (bacteria, viruses, tumor cells).

The indirect way to boost thymosin-A1 is to supplement the diet with zinc since thymosin-A1 is a zinc-dependent string of 28 amino acids (peptide).  Zinc supplementation raises T-cell counts.

Zinc supplementation raises thymus hormone levels among zinc-deficient individuals by 5-fold.

Over a decade ago thymosin, thymosin + zinc and zinc alone were listed as having positive effects upon a weakened immune system.

Zinc deficiency not only results in the involution (shrinkage) of the thymus gland from the size of a walnut to the size of a pea with advancing age, and impairs the ability of the thymus gland to produce peptide (amino acid) hormones such as thymosin-A1.

Thymosin-A1 and cancer survival

Researchers are now calling for a “reappraisal of thymosin-A1 for cancer therapy.”

Thymosin-A1, zinc and zinc + thymosin-A1 have been found to produce similar positive effects among cancer patients.

Thymosin and melanoma

There are published reports of prolonged remissions of cancer among zinc supplemented patients.  The most remarkable is the report of 57.8-month (almost 5-year) survival when metastatic (spreading) melanoma patients were given thymosin-A1 + a monoclonal antibody drug.  Survival was only 7.4 months with the monoclonal antibody alone.

Zinc supplementation and cancer

An unexpected discovery was the use of zinc ionophores (binders) that drag more zinc inside living cells for the treatment of malaria that resulted in a reduction in cancer mortality.

Zinc reduces skin tumor development in laboratory animals.

In a human study, among 196 patients given zinc vs. 71 who received no zinc, liver function deteriorated among patients who received no zinc over a 3-year period.  Incidence of liver cancer was 24.9% among patients given no zinc vs. 9.5% among patients given supplemental zinc.

Have you ever heard of an oncologist who prescribes zinc?

If you ponder what you have just read about thymosin-1A and zinc, you may realize a major breakthrough in cancer has occurred during the COVID-19 pandemic that has gone unreported by health authorities and the news media.  Self-care will be the only way the public will take advantage of this breakthrough.

Thymus gland extracts

Animal derived (calves) thymus gland extracts are available as dietary supplements.  Two sources would be Nature’s Way Thymulus and Ecological Formulas Lyphoactivated Thymic Peptides. (Again, only to be taken when ill.)

Zinc supplements

There are many forms of zinc supplements (zinc acetate, citrate, gluconate, monomethionine, picolinate, oxide, the latter being less absorbable).  Zinc carnosine (polaprezinc) is easier on the digestive tract and is advised for the eradication of H. pylori, a bacterium that causes gastric ulcers.   A 30 mg dose of daily zinc is advised for adults by Dr. Ananda Prasad, the reigning authority on zinc nutriture.  Zinc lozenges (preferably with ionophores) are recommended in the Critical Care Management Protocol, taken 5 times a day, especially when symptoms of breathlessness or loss of smell and taste occur, (which are signs of zinc deficiency) or when a cold, flu or coronavirus infection occurs.  Zinc lozenges are considered the closest thing to a cure for the common cold.

lewrockwell.com/2021/01/no_author/when-no-one-was-looking-dietary-supplements-cured-cancer-covid-19

Gore ↑

%d blogeri kao ovaj: